Enfortumab vedotin in ECOG-PS 2 advanced urothelial carcinoma patients: a real-world study from the ARON-2(EV) project. Rizzo A, Ciccimarra F, de Casio Zequi S, Bove S, et al. BMC Cancer 2026;26:756.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Rizzo A, Ciccimarra F, de Casio Zequi S, Bove S, et al. Enfortumab vedotin in ECOG-PS 2 advanced urothelial carcinoma patients: a real-world study from the ARON-2(EV) project. BMC Cancer 2026;26:756.
PMID: 42063024